[Therapy of perinatal brain injury outcomes: results of a multicenter double-blind placebo-controlled randomized study of tenoten for children (liquid dosage form)].

Autor:	Keshishyan ES; Veltyshev Research Institute, Pirogov National Research Medical University, Moscow, Russia., Bykova OV; Sechenov University Childrens Clinical Hospital, Sechenov First Moscow State Medical University, Moscow, Russia., Borisova MN; Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russia., Minaycheva LI; LLC 'Nebbiollo' Clinical Research Center, Tomsk, Russia., Chernaya NL; Children's Polyclinic №5, Yaroslavl State Medical University, Yaroslavl, Russia., Panteleeva MV; Vladimirsky Moscow Regional Research and Clinical Institute, Moscow, Russia., Sagutdinova ES; Polyclinic №1, Clinical Research Center 'Bonum', Ekaterinburg, Russia., Perminova OA; City Children Clinical Hospital №5, Perm, Russia., Panina OS; LCC DNA research center, Saratov, Russia., Romanova TA; Ivanova Samara Children Clinical Hospital №1, Samara, Russia., Gaynetdinova DD; Kazan State Medical University, Kazan, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2019; Vol. 119 (7. Vyp. 2), pp. 33-39.
DOI:	10.17116/jnevro201911907233
Abstrakt:	Objective: To evaluate the efficacy and safety of tenoten for children (a novel liquid pediatric formulation) in the treatment of perinatal brain injury (PBI) outcomes. Material and Methods: The multicenter double-blind placebo-controlled randomized trial enrolled 184 children (aged 29 days-9 months) with the total score 12-27 according to Djurba-Mastukova scale and the level of physical development 25-75 centiles. Patients were randomized into tenoten (10 drops per day) and placebo groups. Treatment period was 12 weeks ± 5 days. Percentage of patients with ≥4 points improvement according to Djurba-Mastukova scale (responder rate) was used as a primary efficacy endpoint. Results and Conclusion: Patients in the tenoten group had a significant result on primary efficacy endpoint: 77.5% of participants responded to therapy (p=0.02 vs. placebo). In addition, the safety of tenoten for children in the treatment of PBI outcomes is shown. Tenoten for children (a novel liquid pediatric formulation) has been shown to be an effective medication in treatment of PBI outcomes that helps to achieve therapeutic results with minimal side-effects, good tolerability and the high level of adherence to therapy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu